Calliditas Therapeutics AB (Calliditas Therapeutics AB) Days Sales Outstanding : 30.48 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Calliditas Therapeutics AB Days Sales Outstanding?

Calliditas Therapeutics AB's average Accounts Receivable for the three months ended in Dec. 2023 was $14.71 Mil. Calliditas Therapeutics AB's Revenue for the three months ended in Dec. 2023 was $44.02 Mil. Hence, Calliditas Therapeutics AB's Days Sales Outstanding for the three months ended in Dec. 2023 was 30.48.

The historical rank and industry rank for Calliditas Therapeutics AB's Days Sales Outstanding or its related term are showing as below:

CALT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 35.78 Med: 65.63 Max: 19455.25
Current: 48.21

During the past 9 years, Calliditas Therapeutics AB's highest Days Sales Outstanding was 19455.25. The lowest was 35.78. And the median was 65.63.

CALT's Days Sales Outstanding is ranked better than
71.01% of 890 companies
in the Biotechnology industry
Industry Median: 71.92 vs CALT: 48.21

Calliditas Therapeutics AB's Days Sales Outstanding declined from Sep. 2022 (38.29) to Dec. 2023 (30.48).

Calliditas Therapeutics AB Days Sales Outstanding Historical Data

The historical data trend for Calliditas Therapeutics AB's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calliditas Therapeutics AB Days Sales Outstanding Chart

Calliditas Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

92.00

17,168.90

35.78

39.12

Calliditas Therapeutics AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															38.29	26.26	38.62	43.55	30.48

Competitive Comparison of Calliditas Therapeutics AB's Days Sales Outstanding

For the Biotechnology subindustry, Calliditas Therapeutics AB's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Calliditas Therapeutics AB's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calliditas Therapeutics AB's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Calliditas Therapeutics AB's Days Sales Outstanding falls into.

Calliditas Therapeutics AB Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Calliditas Therapeutics AB's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (7.584	+	17.635)	/	2 )	/	117.658	*	365
=	12.6095					/	117.658	*	365
=	39.12

Calliditas Therapeutics AB's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (11.775	+	17.635)	/	2 )	/	44.022	*	365 / 4
=	14.705					/	44.022	*	365 / 4
=	30.48

Calliditas Therapeutics AB (NAS:CALT) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Calliditas Therapeutics AB Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Calliditas Therapeutics AB's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Calliditas Therapeutics AB (Calliditas Therapeutics AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (NAS:CALT) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

CALTX:Sweden CALTXs:UK LC8:Germany

Address

Kungsbron 1, D5, Stockholm, SWE, SE-111 22

Website

https://www.calliditas.se

Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.